High population immunity from widespread prior infections and vaccinations, combined with the incremental evolution of existing Omicron-descendant lineages like XFG and NB.1.8.1, supports the strong trader consensus against a new variant of concern emerging before 2027. These sublineages continue to dominate surveillance data without triggering elevated severity or major immune escape that meets WHO criteria for a variant of concern, as seen in recent seasonal case rises in regions like Thailand and the U.S. Updated monovalent vaccines targeting XFG for the 2026-2027 season further reflect proactive adaptation to circulating strains rather than disruptive shifts. While variants under monitoring such as BA.3.2 and PQ.16.1.1 show ongoing genetic changes, their limited fitness and cocirculation patterns suggest barriers to rapid dominance, aligning with the 90.5% implied probability for no new designation.